PAMPA - Critical factors for better predictions of absorption

被引:204
作者
Avdeef, Alex
Bendels, Stefanie
Di, Li
Faller, Bernard
Kansy, Manfred
Sugano, Kiyohiko
Yamauchi, Yukinori
机构
[1] pION Inc, Woburn, MA 01801 USA
[2] F Hoffmann La Roche & Co Ltd, Div Pharmaceut, PRBDC, CH-4070 Basel, Switzerland
[3] Wyeth Ayerst Res, Chem & Screening Sci, Chem Technol, Princeton, NJ 08543 USA
[4] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland
[5] Pfizer Inc, Nagoya Labs, Global Res & Dev, Aichi 4702393, Japan
关键词
permeability; PAMPA; PAMPA-BBB; oral absorption; human jejunal permeability; structure-property relationships; in vivo/in vitro correlations; octanol-water log P; Caco-2;
D O I
10.1002/jps.21068
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
PAMPA, 109 P(OCT), and Caco-2 are useful tools in drug discovery for the prediction of oral absorption, brain penetration and for the development of structure-permeability relationships. Each approach has its advantages and limitations. Selection criteria for methods are based on many different factors: predictability, throughput, cost and personal preferences (people factor). The PAMPA concerns raised by Galinis-Luciani et al. (Galinis-Luciani et al., 2007, J Pharm Sci, this issue) are answered by experienced PAMPA practitioners, inventors and developers from diverse research organizations. Guidelines on how to use PAMPA are discussed. PAMPA and PAMPA-BBB have much better predictivity for oral absorption and brain penetration than 109 POCT for real-world drug discovery compounds. PAMPA and Caco-2 have similar predictivity for passive oral absorption. However, it is not advisable to use PAMPA to predict absorption involving transporter-mediated processes, such as active uptake or efflux. Measurement of PAMPA is much more rapid and cost effective than Caco-2 and 109 POCT. PAMPA assay conditions are critical in order to generate high quality and relevant data, including permeation time, assay pH, stirring, use of cosolvents and selection of detection techniques. The success of using PAMPA in drug discovery depends on careful data interpretation, use of optimal assay conditions, implementation and integration strategies, and education of users. (C) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:2893 / 2909
页数:17
相关论文
共 60 条
[21]  
HANSCH C, 1979, UNSTITUENT CONSTANTS
[22]  
HOGBEN CAM, 1959, J PHARMACOL EXP THER, V125, P275
[23]  
Japertas P, 2002, QUANT STRUCT-ACT REL, V21, P23, DOI 10.1002/1521-3838(200205)21:1<23::AID-QSAR23>3.0.CO
[24]  
2-E
[25]   Estimation of pKa for druglike compounds using semiempirical and information-based descriptors [J].
Jelfs, Stephen ;
Ertl, Peter ;
Selzer, Paul .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2007, 47 (02) :450-459
[26]  
Kansy M, 2004, BIOTECHNOL PHARM ASP, V1, P197
[27]   Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes [J].
Kansy, M ;
Senner, F ;
Gubernator, K .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (07) :1007-1010
[28]  
Kansy Manfred, 2004, Drug Discov Today Technol, V1, P349, DOI 10.1016/j.ddtec.2004.11.013
[29]   Pharmaceutical profiling in drug discovery [J].
Kerns, EH ;
Di, L .
DRUG DISCOVERY TODAY, 2003, 8 (07) :316-323
[30]   Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery [J].
Kerns, EH ;
Di, L ;
Petusky, S ;
Farris, M ;
Ley, R ;
Jupp, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (06) :1440-1453